Last checked at 
PureTech Health PLC - clinical-stage biotherapeutics company - Investee Akili Interactive will collaborate with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to evaluate Akili digital therapeutic AKL-T01 as a treatment for patients with cognitive dysfunction following Covid-19. There are currently no approved treatments for cognitive impairments in Covid-19 survivors.
Under each collaboration, PureTech says Akili will work with research teams at each institution to conduct two separate randomised, controlled clinical studies evaluating AKL-T01's ability to target and improve cognitive functioning in Covid-19 survivors. AKL-T01 is the first and only digital therapeutic designed to improve attention function. The partners aim to begin clinical recruitment for the studies in the next month.
Current stock price: 414.50 pence, down 1.3% on Wednesday
Year-to-date change: up 3.6%
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
